Welcome to our dedicated page for Sophia Genetics Sa news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on Sophia Genetics Sa stock.
SOPHiA GENETICS SA (SOPH) is a leader in AI-powered genomic analysis, enabling data-driven healthcare through its cloud-native SOPHiA DDM™ Platform. This page aggregates official company news and press releases, providing stakeholders with timely updates on advancements in precision medicine.
Access curated information on financial results, strategic partnerships, and technology innovations that shape the future of clinical diagnostics. Track developments in oncology solutions, regulatory milestones, and research collaborations across their global network of 1,000+ healthcare institutions.
Our repository includes updates on:
- FDA-cleared genomic profiling tools
- AI-driven diagnostic platform enhancements
- Cross-industry research initiatives in rare diseases
- Operational expansions and executive appointments
Bookmark this page for streamlined access to verified SOPHiA GENETICS updates, combining Swiss precision with cutting-edge analytics to transform patient care worldwide.
SOPHiA GENETICS (Nasdaq: SOPH) announced that L'hôpital Universitaire Avicenne in Bobigny, France, is implementing the SOPHiA DDM™ Platform to enhance its testing and research of blood-related cancers and disorders. The hospital, serving approximately 500,000 patients annually, will use the platform to expand its lymphoid testing, advancing research and treatment planning for blood disorders and cancers.
The SOPHiA DDM™ Platform utilizes next-generation sequencing (NGS) to target key variants from various samples, aiding in better detection of disease-associated variants. The platform's AI-based technology facilitates fast and accurate analysis of genomic data, providing nearly 100% reproducible results to ensure stable and trustworthy sequencing data.
SOPHiA GENETICS (Nasdaq: SOPH) announced an expanded relationship with OncoHelix, a Canada-based research and diagnostics laboratory. OncoHelix will implement MSK-ACCESS® powered with SOPHiA DDM™, becoming the first laboratory in Canada to adopt this liquid biopsy solution. This expansion builds on OncoHelix's existing use of the SOPHiA DDM™ Platform for myeloid testing.
The new liquid biopsy solution will advance OncoHelix's oncology testing capabilities, offering an alternative to traditional solid tumor biopsy. It extracts cell-free DNA from blood plasma, revealing circulating tumor DNA, which can expedite clinical decisions and streamline monitoring. The implementation is expected to go live later this summer, supporting OncoHelix's mission to offer exceptional clinical-grade molecular and immune profile testing.
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company specializing in data-driven medicine, has announced the release date for its second quarter 2024 financial results. The results will be unveiled on August 6, 2024, before U.S. markets open. Following the release, the company will host a conference call at 8:00 a.m. EDT / 2:00 p.m. CET to discuss the financial results and provide a business outlook. Investors and interested parties can access the webcast live on the SOPHiA GENETICS Investor Relations Website, where a replay will also be available after the call.
SOPHiA GENETICS (Nasdaq: SOPH) has announced that Dhiti Omics Technologies, an India-based precision molecular diagnostics provider, is now live on the SOPHiA DDM™ Platform. This collaboration aims to enhance Dhiti Omics' capabilities in solid tumor testing by utilizing SOPHiA DDM™ for the Agilent SureSelect Cancer Comprehensive Genomic Profiling (CGP) application. The integration is expected to provide researchers with actionable information on mutations and biomarkers across hundreds of genes, ensuring rapid and accurate diagnostics. Both companies emphasize this partnership's potential in advancing precision medicine and improving health outcomes in India and globally.
SOPHiA GENETICS (Nasdaq: SOPH), a leader in data-driven medicine, announced the results of its 2024 Annual General Meeting (AGM) held on June 24, 2024. Shareholders approved all proposals presented during the meeting held at the company's headquarters in Rolle, Switzerland. Detailed voting results and AGM minutes will be available on the company's website and filed with the U.S. Securities and Exchange Commission on Form 6-K. SOPHiA GENETICS expressed gratitude to its shareholders for their support.
SOPHiA GENETICS has announced the launch of its new Residual Acute Myeloid (RAM) Application, aimed at enhancing measurable residual disease (MRD) testing. This application is designed to support the monitoring of Acute Myeloid Leukemia (AML), one of the most common types of leukemia in adults. Over 50% of AML patients relapse within three years of remission, making post-treatment monitoring critical. The RAM Solution, part of SOPHiA's DDM Platform, offers next-generation sequencing (NGS)-based MRD testing with high sensitivity, detecting one cancer cell among 10,000. This tool provides longitudinal variant monitoring, comprehensive MRD reports, and rapid results within four days. The solution will be available globally this summer and aims to improve patient outcomes by detecting early signs of relapse.
SOPHiA GENETICS (Nasdaq: SOPH) has announced that Kepler Uniklinikum, Austria's second largest hospital, has gone live with its SOPHiA DDM™ Platform. The hospital will use this platform to enhance its next-generation sequencing (NGS) testing and diagnostics specifically for blood cancers. Kepler Uniklinikum, housing 1,800 beds, aims to deepen its in-house NGS testing capabilities and expand services for patients with blood cancers and disorders. The SOPHiA DDM™ Platform provides nearly 100% reproducible results, supporting timely, cost-effective, and reliable sequencing data to aid in the rapid and accurate detection of genomic variants. This move is expected to benefit not only the local population but also provide valuable insights to other users of the platform globally.
SOPHiA GENETICS (Nasdaq: SOPH) has announced the launch of SOPHiA UNITY, a global consortium aimed at accelerating cancer research, drug development, and data-driven patient care. This initiative will unite leading healthcare institutions to harness large-scale, diverse data from multiple modalities, such as imaging, genomics, pathology, and clinical notes. The consortium will utilize the SOPHiA CarePath™ module on the SOPHiA DDM™ Platform to aggregate and analyze complex real-world data, offering valuable insights to members. Memorial Sloan Kettering Cancer Center is the first institution to join SOPHiA UNITY, with more members to be announced soon.
SOPHiA GENETICS (Nasdaq: SOPH) announced a collaboration with Microsoft and NVIDIA to launch a whole genome sequencing (WGS) analytical solution by end of 2024. The new WGS application aims to deliver fully analyzed genome insights within the same day, enhancing research, drug discovery, and clinical care. Leveraging Microsoft Azure and NVIDIA Parabricks, the solution will provide scalable and rapid genomic analysis, aiding researchers and clinicians in making data-driven decisions. The SOPHiA DDM™ platform integrates genomic data with other diagnostic modalities, aiming to support treatment planning and drug development efforts, particularly for cancer and rare genetic disorders.
SOPHiA GENETICS (Nasdaq: SOPH) announced that Instituto Mário Penna is now utilizing its SOPHiA DDM™ Platform. This Brazilian oncology center, located in Belo Horizonte, will use the platform to enhance its research and testing for blood cancers. The SOPHiA DDM™ Platform employs next-generation sequencing (NGS) to accurately target key variants from various sample types, aiding in timely and precise detection.
The Instituto Mário Penna, a major oncology service provider in Brazil, offers comprehensive cancer care including in-patient, out-patient, chemotherapy, radiation treatments, clinical laboratory analysis, and surgery. The integration of SOPHiA DDM™ aims to improve on-site diagnostic capabilities and support data-driven treatment decisions.
Blood cancers are the fifth most common type of cancer globally, and the institute's adoption of this AI-based technology reflects a commitment to advancing healthcare in Brazil.